Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 May;11(5):1067-1081.
doi: 10.1158/2159-8290.CD-20-1211. Epub 2021 Jan 27.

Metabolic Codependencies in the Tumor Microenvironment

Affiliations
Review

Metabolic Codependencies in the Tumor Microenvironment

Prasenjit Dey et al. Cancer Discov. 2021 May.

Abstract

Metabolic reprogramming enables cancer cell growth, proliferation, and survival. This reprogramming is driven by the combined actions of oncogenic alterations in cancer cells and host cell factors acting on cancer cells in the tumor microenvironment. Cancer cell-intrinsic mechanisms activate signal transduction components that either directly enhance metabolic enzyme activity or upregulate transcription factors that in turn increase expression of metabolic regulators. Extrinsic signaling mechanisms involve host-derived factors that further promote and amplify metabolic reprogramming in cancer cells. This review describes intrinsic and extrinsic mechanisms driving cancer metabolism in the tumor microenvironment and how such mechanisms may be targeted therapeutically. SIGNIFICANCE: Cancer cell metabolic reprogramming is a consequence of the converging signals originating from both intrinsic and extrinsic factors. Intrinsic signaling maintains the baseline metabolic state, whereas extrinsic signals fine-tune the metabolic processes based on the availability of metabolites and the requirements of the cells. Therefore, successful targeting of metabolic pathways will require a nuanced approach based on the cancer's genotype, tumor microenvironment composition, and tissue location.

PubMed Disclaimer

Conflict of interest statement

CONFLICT OF INTEREST DISCLOSURE

P.D. has nothing to disclose. A.C.K. has financial interests in Vescor Therapeutics, LLC. A.C.K. is an inventor with patents pertaining to KRAS-regulated metabolic pathways, redox control pathways in pancreatic cancer, targeting GOT1 as a therapeutic approach, and the autophagic control of iron metabolism. A.C.K. is on the SAB of Rafael/Cornerstone Pharmaceuticals. A.C.K. is a consultant for Deciphera Pharmaceuticals. R.A.D. is a co-founder, advisor, and/or director of Tvardi Therapeutics, Asylia Therapeutics, Stellanova Therapeutics, Nirogy Therapeutics and Sporos Bioventures. Tvardi and Nirogy are developing STAT3 and MCT inhibitors, respectively.

Figures

Figure 1.
Figure 1.. Intrinsic drivers of metabolic pathways.
This schematic summarizes specific oncogenes and tumor suppressor genes that modulate metabolic pathways for tumor progression. PI3K-AKT, mTOR and cMyc pathway are integral to the maintenance of core metabolic functions in normal and cancer cells, while aberrant activation is central to tumor progression and maintenance. GLUT, Glucose transporter; HK1/2, Hexokinase 1/2; PFKM1, phosphofructokinase-M 1; ENO1, Enolase 1; MCT1, Monocarboxylate transporter 1; ACC1, Acetyl-CoA carboxylase; ACLY, ATP Citrate Lyase; HMGCR, HMG-CoA reductase.
Figure 2.
Figure 2.. Extrinsic drivers of metabolic pathways.
This schematic summarizes the factors derived from the microenvironment that dictate the metabolic profile of the tumor. Extrinsic factors such as cytokines, hormones and metabolites regulate cellular metabolism in discrete ways driven by the availability of these factors in anatomically distinct sites and by differences in the composition of resident immune, endothelial, and fibroblast cells. MPC, Mitochondrial Pyruvate; SREBP, Sterol regulatory element-binding protein.

Similar articles

Cited by

References

    1. Koppenol WH, Bounds PL, Dang CV. Otto Warburg's contributions to current concepts of cancer metabolism. Nat Rev Cancer 2011;11(5):325–37 doi 10.1038/nrc3038. - DOI - PubMed
    1. Lunt SY, Vander Heiden MG. Aerobic glycolysis: meeting the metabolic requirements of cell proliferation. Annu Rev Cell Dev Biol 2011;27:441–64 doi 10.1146/annurev-cellbio-092910-154237. - DOI - PubMed
    1. Pavlova NN, Thompson CB. The Emerging Hallmarks of Cancer Metabolism. Cell Metab 2016;23(1):27–47 doi 10.1016/j.cmet.2015.12.006. - DOI - PMC - PubMed
    1. Locasale JW, Cantley LC. Metabolic flux and the regulation of mammalian cell growth. Cell Metab 2011;14(4):443–51 doi 10.1016/j.cmet.2011.07.014. - DOI - PMC - PubMed
    1. Vander Heiden MG, Cantley LC, Thompson CB. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 2009;324(5930):1029–33 doi 10.1126/science.1160809. - DOI - PMC - PubMed

Publication types